You just read:

Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer

News provided by

Hansoh Pharma

19 Mar, 2020, 11:07 GMT